<DOC>
	<DOCNO>NCT01991795</DOCNO>
	<brief_summary>The purpose study compare effect ticagrelor versus placebo patient Type 2 Diabetes Mellitus .</brief_summary>
	<brief_title>A Study Comparing Cardiovascular Effects Ticagrelor Versus Placebo Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>A multinational , randomised , double-blind , placebo-controlled phase IIIb trial evaluate effect ticagrelor twice daily incidence cardiovascular death , myocardial infarction stroke patient type 2 diabetes mellitus</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<mesh_term>Adenosine</mesh_term>
	<criteria>Men woman â‰¥50 year age type 2 diabetes mellitus treatment glucose lower medication since least 6 month , either document coronary artery occlusive disease previous revascularization coronary artery . Key History myocardial infarction stroke ; plan treatment agent inhibit blood clotting ; plan use ASA/Aspirin dose 150 mg daily ; plan coronary , cerebrovascular , peripheral arterial revascularization ; patient know bleed disorder patient need chronic oral anticoagulant therapy chronic lowmolecularweight heparin ; history intracranial bleeding time , history bleed gastrointestinal tract within last 6 month major surgery within last 30 day ; patient know severe liver disease kidney failure require dialysis</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Coronary artery disease</keyword>
	<keyword>Outcome</keyword>
	<keyword>Prevention</keyword>
	<keyword>Antiplatelet</keyword>
</DOC>